Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: Research at the bleeding edge. Literally.

How many university students can say they invented a product that people around the world will want to use? For that matter, how many people have ever invented a product that made it to the market?! Joe Landolina is CEO and Co-Founder of Suneris, Inc. and a student at...

Social media and stem cells: Time to start tweeting

Why should stem cell researchers use Twitter? Powerful news aggregator/information filter Able to engage/converse with other attendees at conferences & meetings Increase traffic, discussion and citations of your papers Create professional networks and...

Right Turn: stem cell comic relief

Last week we launched a new feature — Right Turn — to showcase the “lighter” side of regenerative medicine. Every Friday, we will be bringing you cartoons, photos, videos and other content that may be just as thought provoking as the written submissions...

Lego® and biomaterials: the building blocks of life

When I was a child, I would sit on my living room floor playing with my Lego set for hours on end. I recall building police cars, giant spaceships and all kinds of other amazing structures. My weekend mornings always began the same way: I would dump my box of Legos...

Right Turn: our new Friday feature

Signals Blog has given itself the green light to try something different. We’re launching a brand new feature, to appear on Fridays, which will showcase the “lighter” side of regenerative medicine. We will be bringing you cartoons, photos, videos and other content...

Update: $600M insider trading fine is largest ever

. As a follow up to last month’s post describing how leaked information about an Alzheimer’s drug clinical trial led to the largest ever case of insider trading and destroyed the careers of Dr. Sidney Gilman, a well-respected clinician, and Matthew Martoma, a young...

BioTime: A new Geron, without a decade of baggage

[pullquote]In time, this purchase might make BioTime the company that Geron was supposed to be.[/pullquote]Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!